RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Pratibha V. Nerurkar to Momordica charantia

This is a "connection" page, showing publications Pratibha V. Nerurkar has written about Momordica charantia.
Connection Strength

3.199
  1. Nerurkar PV, Orias D, Soares N, Kumar M, Nerurkar VR. Momordica charantia (bitter melon) modulates adipose tissue inflammasome gene expression and adipose-gut inflammatory cross talk in high-fat diet (HFD)-fed mice. J Nutr Biochem. 2019 06; 68:16-32.
    View in: PubMed
    Score: 0.665
  2. Snee LS, Nerurkar VR, Dooley DA, Efird JT, Shovic AC, Nerurkar PV. Strategies to improve palatability and increase consumption intentions for Momordica charantia (bitter melon): a vegetable commonly used for diabetes management. Nutr J. 2011 Jul 28; 10:78.
    View in: PubMed
    Score: 0.391
  3. Nerurkar PV, Johns LM, Buesa LM, Kipyakwai G, Volper E, Sato R, Shah P, Feher D, Williams PG, Nerurkar VR. Momordica charantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. J Neuroinflammation. 2011 Jun 03; 8:64.
    View in: PubMed
    Score: 0.387
  4. Nerurkar PV, Lee YK, Nerurkar VR. Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complement Altern Med. 2010 Jun 29; 10:34.
    View in: PubMed
    Score: 0.363
  5. Nerurkar P, Ray RB. Bitter melon: antagonist to cancer. Pharm Res. 2010 Jun; 27(6):1049-53.
    View in: PubMed
    Score: 0.355
  6. Ray RB, Raychoudhuri A, Steele R, Nerurkar P. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res. 2010 Mar 01; 70(5):1925-31.
    View in: PubMed
    Score: 0.354
  7. Nerurkar PV, Lee YK, Motosue M, Adeli K, Nerurkar VR. Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. Br J Nutr. 2008 Oct; 100(4):751-9.
    View in: PubMed
    Score: 0.309
  8. Nerurkar PV, Lee YK, Linden EH, Lim S, Pearson L, Frank J, Nerurkar VR. Lipid lowering effects of Momordica charantia (Bitter Melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2. Br J Pharmacol. 2006 Aug; 148(8):1156-64.
    View in: PubMed
    Score: 0.275
  9. Ru P, Steele R, Nerurkar PV, Phillips N, Ray RB. Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model. Cancer Prev Res (Phila). 2011 Dec; 4(12):2122-30.
    View in: PubMed
    Score: 0.099
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support